SLC7A11 and hepatocellular carcinoma: In sorafenib-resistant HCC cells, YAP/TAZ is activated in the nucleus and binds to DNA fragments containing the transcriptional enhanced associate domain motif in the SLC7A11 gene promoter, thereby inducing the expression of SLC7A11, increasing the cellular level of glutathione, decreasing ROS levels, and inhibiting ferroptosis [30,31].